Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PharmaCielo ( (TSE:PCLO) ) just unveiled an update.
PharmaCielo reported results for the quarter and nine months ended December 31, 2025, highlighting a swing to positive adjusted EBITDA of $293,000 from a loss of $2.3 million a year earlier, despite revenue declining to $1.8 million from $3.2 million. Management said the improvement reflects cost controls, organizational rightsizing and a strategic shift toward higher-margin export opportunities, while the company continues to post a net loss of $2.3 million or $0.01 per share.
Chairman and CEO Marc Lustig described the period as a turning point, noting that the company has rebuilt a foundation to pursue consistent export volumes, deeper relationships with strategic international partners and repeat purchase agreements to support more predictable revenue growth. PharmaCielo also set April 2, 2026, as the date for its next annual general and special meeting in Toronto, where shareholders will vote on directors, auditors and other routine corporate matters.
The most recent analyst rating on (TSE:PCLO) stock is a Hold with a C$0.08 price target. To see the full list of analyst forecasts on PharmaCielo stock, see the TSE:PCLO Stock Forecast page.
Spark’s Take on TSE:PCLO Stock
According to Spark, TipRanks’ AI Analyst, TSE:PCLO is a Neutral.
The score is primarily held down by weak financial performance (declining revenue, deeply negative margins, ongoing cash burn, and negative equity). Technicals are supportive due to the price trading above major moving averages and a positive MACD, but the extremely overbought RSI increases near-term risk. Valuation is difficult to assess with negative earnings and no stated dividend yield.
To see Spark’s full report on TSE:PCLO stock, click here.
More about PharmaCielo
PharmaCielo Ltd. is a Canada-headquartered global cannabis company focused on the ethical and sustainable cultivation, processing and supply of all-natural, pharmaceutical-grade medicinal and commercial dried cannabis flower and related products. Its principal wholly owned subsidiary, PharmaCielo Colombia Holdings S.A.S., operates a cultivation and processing centre in Rionegro, Colombia, serving large channel distributors in international markets.
YTD Price Performance: 11.11%
Average Trading Volume: 122,032
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$7.69M
See more insights into PCLO stock on TipRanks’ Stock Analysis page.